The Alkaloid #28: The Medicine Needs More Than a Molecule

Science, culture and capital — one dose at a time

The Dose

The FDA wants input on what patients should be told about touch during psychedelic treatment. It also wants to know how practitioners should report ethical violations and who coordinates care when a patient needs help after the session.[1]

These are some of the questions in the agency's notice for its September 14 public hearing on potential therapeutic uses of psychedelic drugs. Alongside training and safety, the notice asks about insurance coverage, clinic capacity and tracking outcomes over time. Written comments remain open through October 5.[1][2]

For anyone hoping these treatments become useful, accessible medicine, that is a worthwhile reading list. A drug can arrive with carefully measured ingredients. The people, appointments and safeguards around it take their own work.

This issue examines the published questions, not what speakers said or what the hearing concluded. The notice explicitly excludes judgments about the safety or effectiveness of individual products, drug scheduling and legalization. It is a request for input on potential future care, not a treatment approval.[1]

The practical question is how to care for someone before, during and after a vulnerable experience. A comfortable chair is a reasonable start. It cannot cover a shift.

Quick Hits

• The comment window is still open. The FDA lists October 5, 2026, at 11:59 p.m. Eastern as the electronic submission deadline. The notice says timely written comments receive equal consideration with oral presentations. The docket is FDA-2026-N-7542.[1][2]
• Training extends beyond the dosing session. The agency asks about personnel needs for screening and preparation, administration and monitoring, and follow-up. It includes the possible roles of licensed counselors and peer support specialists.[1]
• Telehealth has a specific place in the questions. The notice asks about remote screening, follow-up and care coordination. That is not an authorization for unsupervised dosing at home.[1]
• Faster review is not approval. The notice states that national priority vouchers and Breakthrough Therapy designation neither establish safety and effectiveness nor substitute for marketing approval.[1]

That's the news. The analysis is below — Science Desk, Market Watch, and a closing thought.

Science Desk

The care is also part of the experiment

Psychedelic research has a measurement problem that a pill count cannot solve. If a treatment produces conspicuous changes in perception, participants may work out which study group they are in. So may the people looking after them.

The FDA's June 2023 draft guidance on clinical investigations describes this as functional unblinding. Expectations can then influence how participants experience or report improvement, and how observers assess it. The document discusses ways to reduce and measure that bias, including independent raters and questionnaires about treatment expectations.[3]

This does not mean a reported benefit is imaginary. It means a convincing trial has to do more work to distinguish a drug's effect from expectations and other influences.

Psychological support adds another variable. In that draft, the FDA asks developers to explain their care model and describes trial designs that could help separate the contributions of the drug and psychotherapy. Those are different questions from whether someone needs protection and monitoring during an altered state.[3]

A service can need a safety protocol even while researchers are still testing which therapeutic elements improve outcomes. Keeping those questions separate helps avoid two mistakes: treating every part of a trial's care package as proven treatment, or assuming that uncertainty about psychotherapy makes supervision unnecessary.

Consent needs more than a signature

The hearing notice is specific about the risks it wants considered. It asks what informed consent should say about an amplified power imbalance between patient and provider, therapeutic touch, psychological distress and a difficult psychedelic experience. It also asks how to prevent, detect and report ethical violations.[1]

These are requests for proposed safeguards, not findings about a particular practitioner. They put an important responsibility on any future care model: patients should understand boundaries before treatment, and have a clear route to raise concerns afterward.

The notice also asks about screening for medical and psychiatric conditions associated with greater risk, and coordination with emergency or crisis services when needed. Safety continues after the most visible drug effects have passed.[1]

Follow-up has a scientific job, too. The FDA is asking about common data elements for the drug, dose, condition being treated, setting and patient characteristics, alongside privacy protections and longer-term tracking. Without comparable records, it becomes harder to tell whether differences in outcomes reflect the treatment, the people receiving it or the way care was delivered.[1]

Market Watch

The appointment has a cost, too

The access section reads more like a clinic manager's working notes than a pharmaceutical launch announcement. It asks about workforce, space, scheduling, storage, security and capacity. It also asks what evidence insurers need for coverage and payment decisions.[1]

That makes sense. A medicine's price would be only one part of the cost of a supervised service. Staff time and rooms remain occupied while care is happening; preparation and follow-up require capacity of their own.

The earlier FDA draft gives a concrete illustration of that labor: it describes observation by two monitors throughout a clinical-trial treatment session. This is draft guidance for clinical investigations, not a final staffing rule for future clinics. But it shows why a cost forecast that counts only the drug could miss much of the proposed service.[3]

For developers and providers, the useful commercial questions are therefore quite ordinary. How many people can a clinic responsibly see? Which parts of care would an insurer cover? What happens when a patient needs additional follow-up? The notice asks for evidence on these issues; it does not settle reimbursement or promise affordable access.[1]

There is a tension worth keeping visible. Requirements that take staff and space can limit availability. Cutting them without evidence could transfer the cost to patients in the form of avoidable harm. The case for a less intensive care model would need evidence about its safety and outcomes, not just a more attractive operating budget.

The FDA also acknowledges that some workforce and access questions involve state or other federal authorities. This hearing cannot, by itself, produce a complete national system for delivering care.[1]

The Last Word

The most useful thing about this agenda is its attention to the parts of treatment patients would have to live with: the screening appointment, the person in the room, the bill and the follow-up call.

None of those details resolves whether a particular drug works. They deserve scrutiny alongside that question, before a care model becomes expensive to change.

As the written-comment period continues, look for proposals that make responsibilities clear. A patient should be able to find out who is accountable during treatment, where to report a concern and who will respond if things are not going well afterward. Those are reasonable expectations of medicine.

— The Alkaloid

Sources

[1] FDA: Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments. Federal Register, July 14, 2026; docket FDA-2026-N-7542. Primary agency notice; especially sections III and IV. Questions for public input, not adopted clinical standards or hearing findings.

[2] FDA public hearing page. Lists the September 14, 2026 hearing and October 5 written-comment deadline. Agency event information, not a transcript.

[3] FDA: Psychedelic Drugs: Considerations for Clinical Investigations. June 2023 draft guidance for industry, clinical section, printed pages 9–12. Nonbinding draft guidance, not for implementation; not a peer-reviewed efficacy study or a final rule for routine clinical care.

The Alkaloid publishes every Tuesday. Forward this to someone who needs the dose. Subscribe for full access: TheAlkaloid.com